Nsclc News Today

A recap of the days headlines and a look at whats in store for tomorrow. Dealing in u. S. Dollars, currency abroad, business and precious metals, aluminum, steel and coal. And thats only phase one. In less than three months the administration hits irans Oil Production and banking sector. Shannon thank you very much. Those new sanctions kick in against iran at 12 oh one eastern time. Lindsey graham, member of the Senate Armed Services committee joins us now to dig in further. The sanctions kick i...

Consistent with previous observations, overall survival and progression-free survival remained strong at the follow-up point.

Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2 NSCLC.

Experts on HER2 NSCLC discuss the patient populations in which they’d utilize trastuzumab deruxtecan and share their clinical experiences with the therapy.

Alecensa was shown to reduce the risk of disease recurrence or death by 76% versus chemotherapy for patients with ALK-positive non-small cell lung cancer.

This analysis evaluated patient-related outcomes between those who did and did not receive consolidation durvalumab after chemoradiotherapy for unresectable stage III non–small cell lung cancer.

Definitive treatment to the primary site improves overall and cancer-specific survival among patients with brain-only NSCLC metastases, a recent retrospective study shows.

Frontline amivantamab with chemotherapy has been recommended for approval by the CHMP in EGFR exon 20 insertion+ non–small cell lung cancer.

The panel discusses the role of antibody-drug conjugates (ADCs) and the treatment of patients with HER2 non–small cell lung cancer.

A new study reveals that baseline EGFR mutations may be key to making the decision in the frontline setting.